Hemorrhagic Fever Viruses as Biological Weapons

Luciana Borio(Johns Hopkins Center for Health Security), Thomas V. Inglesby(Johns Hopkins University), C. J. Peters(The University of Texas at Austin), Alan Schmaljohn(United States Army Medical Research Institute of Infectious Diseases), James M. Hughes, Peter B. Jahrling(United States Army Medical Research Institute of Infectious Diseases), Thomas G. Ksiazek, Karl M. Johnson, Andrea Meyerhoff(United States Food and Drug Administration), Tara O’Toole(Johns Hopkins University), Michael S. Ascher(United States Department of Health and Human Services), John Bartlett(Johns Hopkins University), Joel G. Breman(National Institutes of Health), Edward M. Eitzen(United States Army Medical Research Institute of Infectious Diseases), Margaret Hamburg, Jerry Hauer(United States Department of Health and Human Services), D. A. Henderson(Johns Hopkins University), Richard T. Johnson(Johns Hopkins University), Gigi Kwik(Johns Hopkins University), Marci Layton(New York State Department of Health), Scott R. Lillibridge(United States Department of Health and Human Services), Gary J. Nabel(National Institutes of Health), Michael T. Osterholm(University of Minnesota), Trish M. Perl(Johns Hopkins University), Philip K. Russell(United States Department of Health and Human Services), Kevin Tonat(United States Department of Health and Human Services), for the Working Group on Civilian Biodefense
JAMA
May 8, 2002
10.1001/jama.287.18.2391
Cited by 674

Abstract

OBJECTIVE: To develop consensus-based recommendations for measures to be taken by medical and public health professionals if hemorrhagic fever viruses (HFVs) are used as biological weapons against a civilian population. PARTICIPANTS: The Working Group on Civilian Biodefense included 26 representatives from academic medical centers, public health, military services, governmental agencies, and other emergency management institutions. EVIDENCE: MEDLINE was searched from January 1966 to January 2002. Retrieved references, relevant material published prior to 1966, and additional sources identified by participants were reviewed. CONSENSUS PROCESS: Three formal drafts of the statement that synthesized information obtained in the evidence-gathering process were reviewed by the working group. Each draft incorporated comments and judgments of the members. All members approved the final draft. CONCLUSIONS: Weapons disseminating a number of HFVs could cause an outbreak of an undifferentiated febrile illness 2 to 21 days later, associated with clinical manifestations that could include rash, hemorrhagic diathesis, and shock. The mode of transmission and clinical course would vary depending on the specific pathogen. Diagnosis may be delayed given clinicians' unfamiliarity with these diseases, heterogeneous clinical presentation within an infected cohort, and lack of widely available diagnostic tests. Initiation of ribavirin therapy in the early phases of illness may be useful in treatment of some of these viruses, although extensive experience is lacking. There are no licensed vaccines to treat the diseases caused by HFVs.

Related Papers

Biosafety in microbiological and biomedical laboratories
Jonathan Y. Richmond, Robert W. McKinney|U.S. G.P.O. , For sale by the Supt. of Docs., U.S. G.P.O. eBooks|1999|1.5k
Lassa Fever
Joseph B. McCormick, I. J. King, P. A. Webb et al.|New England Journal of Medicine|1986|997
Lassa Fever, a New Virus Disease of Man from West Africa
John D. Frame, J.T. Baldwin, David J. Gocke et al.|American Journal of Tropical Medicine and Hygiene|1970|527
Biohazard: the chilling true story of the largest covert biological weapons program in the world--told from the inside by the man who ran it
|Choice Reviews Online|1999|353
Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus.
E. D. Johnson, N Jaax, John R. White et al.|PubMed|1995|271